Karel Helman

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Diffuse Large B Cell Lymphoma

Acute Lymphoblastic Leukemia

Immune Response

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Anděra, Marek Trněný, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status. Blood advances (2024)
Alexandra Dolnikova, Dmitry Kazantsev, Magdalena Klanova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Liliana Tuskova, Eva Hoferkova, Marek Mraz, Karel Helman, Nikola Curik, Katerina Machova Polakova, Ladislav Andera, Marek Trneny, Pavel Klener
Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood advances 8 (13) (2024)
Magdalena Klanova, Dmitry Kazantsev, Eva Pokorna, Tomas Zikmund, Jana Karolova, Matej Behounek, Nicol Renesova, Dana Sovilj, Cristina D Kelemen, Karel Helman, Radek Jaksa, Ondrej Havranek, Ladislav Andera, Marek Trneny, Pavel Klener
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. Molecular cancer therapeutics (2021)
Elizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, Johanna Richter, Yohannes Gebreselassie, Matthew J Carter, Jana Karolova, Michael Svaton, Karel Helman, Nicola J Weston-Bell, Laura Karydis, Chris T Williamson, Georg Lenz, Jeremy Pettigrew, Curtis Harwig, Freda K Stevenson, Mark S Cragg, Francesco Forconi, Andrew J Steele, Jennifer Cross, Lloyd Mackenzie, Pavel Klener, Graham Packham
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2019)
Dana Prukova, Ladislav Andera, Zuzana Nahacka, Jana Karolova, Michael Svaton, Magdalena Klanova, Ondrej Havranek, Jan Soukup, Karla Svobodova, Zuzana Zemanova, Diana Tuskova, Eva Pokorna, Karel Helman, Kristina Forsterova, Mariana Pacheco-Blanco, Petra Vockova, Adela Berkova, Eva Froňková, Marek Trneny, Pavel Klener
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (14) (2019)